Groupe d'Etude en Oncologie du Quebec

Title	A Multi-Country, Real-World Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients Diagnosed With Myelofibrosis Through Chart Review
Protocole ID	METER
ClinicalTrials.gov ID	NCT05444972
Cancer Type(s)	MPN: Vaquez, Essential Thrombocytemia, Myeloid Metaplasia
Phase	Other
Stage
Study Type	Other
Drug
Institution	CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX 5415 boul. de l'Assomption, Montréal, QC, H1T2M4
City
Principal Investigator	Dr. Natasha Szuber
Coordinator
Status	Recruiting
Activation Date	16-11-2022
Eligibility Criteria	Treated for myelofibrosis (MF) [primary myelofibrosis (PMF) and secondary myelofibrosis (SMF)]. Must have initiated their first treatment on or after the first date when ruxolitinib was approved in their country of residence and no later than 31 December 2021.
Exclusion Criteria	Having received MF treatment in a clinical trial setting.

Groupe d'étude en oncologie du Québec